The Prognostic Value of SOX2 Expression in Non-Small Cell Lung Cancer: A Meta-Analysis
The Prognostic Value of SOX2 Expression in Non-Small Cell Lung Cancer: A Meta-Analysis
复制标题
SOX2 表达在非小细胞肺癌中的预后价值：荟萃分析
DOI：
10.1371/journal.pone.0071140
复制
发表时间：
2013-08-19
期刊：
影响因子：
3.7
通讯作者：
Zhou, Jianwei
中科院分区：
文献类型：
--
作者：
Chen, Yansu;Huang, Yefei;Zhou, Jianwei
目的探讨肿瘤中SOX2表达与非小细胞肺癌（NSCLC）患者临床病理特征及生存的关系。方法 截至 2013 年 5 月，已确定评估 NSCLC 中 SOX2 的临床病理学特征和预后意义的出版物。使用标准统计方法对符合条件的研究进行荟萃分析，以阐明 SOX2 表达与这些临床参数之间的关联。结果共有八项研究符合纳入标准。对这些数据的分析表明，SOX2 表达与鳞状细胞组织学呈正相关（合并 OR = 5.26，95% CI：1.08–25.6，P = 0.040）。同时，我们还发现 SOX2 表达与总生存率呈正相关（合并 HR = 0.65，95% CI：0.47–0.89，P = 0.007，随机效应）。结论 SOX2在肿瘤中的表达是NSCLC患者的候选阳性预后生物标志物。
Objective To investigate the association of SOX2 expression in tumor with clinicopathological features and survival of non-small-cell lung carcinoma (NSCLC) patients. Methods Publications assessing the clinicopathological characteristics and prognostic significance of SOX2 in NSCLC were identified up to May 2013. A meta-analysis of eligible studies was performed using standard statistical methods to clarify the association between SOX2 expression and these clinical parameters. Results A total of eight studies met the inclusion criteria. Analysis of these data showed that SOX2 expression was positively associated with squamous histology, (pooled OR = 5.26, 95% CI: 1.08–25.6, P = 0.040). Simultaneously, we also found that SOX2 expression was positively associated with overall survival (pooled HR = 0.65, 95% CI: 0.47–0.89, P = 0.007, random-effect). Conclusions SOX2 expression in tumor is a candidate positive prognostic biomarker for NSCLC patients.